Tadekinig alfa clinical trials
How each study uses tadekinig alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tadekinig alfa studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
4 studies that test it; most in 2015 (1)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
AB2 Bio Ltd. (3) · University of Pennsylvania (1)
Studies
Open first, then newest update. How each study uses tadekinig alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Tadekinig Alfa (IL-18BP) Rescue Therapy for CAR T Cell Related Cytokine Release Syndrome (CRS) and HLH-like SyndromeRecruitingEarly Phase 1University of PennsylvaniaNCT05306080Written as Tadekinig alfa (IL-18BP)
- Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP DeficiencyCompletedPhase 3AB2 Bio Ltd.NCT03113760Written as Tadekinig alfa
- Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label ExtensionCompletedPhase 3AB2 Bio Ltd.NCT03512314Written as Tadekinig alfa
- Therapeutic Use of Tadekinig Alfa in Adult-onset Still's DiseaseCompletedPhase 2AB2 Bio Ltd.NCT02398435Written as Tadekinig alfa (recombinant human IL-18 binding protein)
Codes
What other systems call tadekinig alfa · ClinicalTrials.gg INT014665
- UNII (FDA) 3G6834I4PFTADEKINIG ALFAOne source FDA
- NCI Thesaurus C152488Tadekinig AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3G6834I4PF | TADEKINIG ALFA | One source FDA |
| NCI Thesaurus | C152488 | Tadekinig Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.